Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review (Q38857820)

7 September 2017

1 reference

title

Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review (English)

1 reference

7 September 2017

6

1 reference

7 September 2017

1

Emilio Martin-Mola

1 reference

7 September 2017

Alejandro Balsa

2

1 reference

7 September 2017

Rosario García-Vicuna

3

1 reference

7 September 2017

Juan Gómez-Reino

4

1 reference

7 September 2017

Miguel Angel González-Gay

5

1 reference

7 September 2017

Estíbaliz Loza

7

1 reference

7 September 2017

publication date

6 June 2016

1 reference

Rheumatology International

7 September 2017

published in

1 reference

7 September 2017

volume

36

1 reference

7 September 2017

issue

8

1 reference

7 September 2017

page(s)

1043-1063

1 reference

The prevalence of rheumatoid arthritis in the general population of Spain.

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Adaptive immunity in rheumatoid arthritis: anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rituximab for rheumatoid arthrits treatment: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Anti-keratin antibodies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Use and significance of anti-CCP autoantibodies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The influence of ACPA status and characteristics on the course of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the 'AMC-Senshu' method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Citrullination of synovial proteins in murine models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The presence of citrullinated proteins is not specific for rheumatoid synovial tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

A prediction rule for the development of arthritis in seropositive arthralgia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Smoking and overweight determine the likelihood of developing rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

HLA class II association with rheumatoid arthritis: facts and interpretations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Genes, environment and immunity in the development of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Periodontal disease and subgingival microbiota as contributors for rheumatoid arthritis pathogenesis: modifiable risk factors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Arthritis and bone loss: a hen and egg story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rheumatoid arthritis: a disease associated with accelerated atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Accelerated atherosclerosis in autoimmune rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Atherosclerotic cardiovascular disease in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Osteoprotegerin concentrations relate independently to established cardiovascular disease in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Accelerated atherosclerosis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Carotid Intima-Media Thickness Predicts the Development of Cardiovascular Events in Patients with Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Predictors of response to TNF antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Immunotherapeutic implication of IL-6 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Abatacept use in rheumatoid arthritis: evidence review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Differences in synovial tissue infiltrates between anti–cyclic citrullinated peptide–positive rheumatoid arthritis and anti–cyclic citrullinated peptide–negative rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis.

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Rituximab therapy in Greek patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

[Genetics of rheumatoid arthritis]

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Serum levels of anticyclic citrullinated peptide antibodies, interleukin-6, tumor necrosis factor-α, and C-reactive protein are associated with increased carotid intima-media thickness: a cross-sectional analysis of a cohort of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

The joy of citrulline: new insights into the diagnosis, pathogenesis, and treatment of rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

[Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Antiperinuclear factor: a useful test for the diagnosis of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Antiperinuclear factor as a prognostic marker in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

B lymphocyte depletion in rheumatoid arthritis: targeting of CD20

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis--a systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Does the presence of anti-CCP autoantibodies and their serum levels influence the severity and activity in rheumatoid arthritis patients?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

Second generation automated anti-CCP test better predicts the clinical diagnosis of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

10.1007/S00296-016-3506-3

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1027268356

0 references

1 reference